在NAVIGATOR中,在患有重症,不受控制的喘患者和并发性鼻的患者中,Tezepelumab的有效性
Tanya M Laidlaw1,2, Andrew Menzies-Gow3, Scott Caveney4
1Jeff and Penny Vinik Center for Allergic Diseases Research, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA.
Journal of asthma and allergy
|September 11, 2023
概括
在重度喘患者中,Tezepelumab显著降低了喘恶化,改善了肺功能和症状,包括那些鼻息肉患者. 这种生物疗法为难以控制的喘提供了一种新的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 过敏和临床免疫学
背景情况:
- 严重的喘影响了大量患者,治疗选择有限.
- 胸膜层淋巴蛋白 (TSLP) 是严重喘中呼吸道炎症的关键驱动因素.
- 德泽佩卢马布针对TSLP,提供了一个潜在的新疗法方法.
研究的目的:
- 评价tezepelumab在患有严重,不受控制的喘患者的疗效,特别关注具有和没有鼻息肉 (NP) 的子组.
- 评估tzepelumab对年度喘恶化率 (AAER),肺功能和症状控制的影响.
主要方法:
- 一项3期,随机,双盲,安慰剂对照研究 (NAVIGATOR) 涉及1059名患有严重喘的患者.
- 患者在52周内每4周接受皮下注射特泽佩卢马布 (210毫克) 或安慰剂.
- 探索性分析评估了NP子组中的AAER,肺功能 (FEV1),中鼻结局测试 (SNOT) -22分数,以及生物标志物 (FeNO,血液中乙烯基蛋白,IgE,IL-5,IL-13).
主要成果:
- 与安慰剂相比,Tezepelumab在52周内在患有NP的患者中减少了85%的AAER,在没有NP的患者中减少了51%的AAER.
- 在两组NP小组中都观察到肺功能,喘控制和与健康相关的生活质量 (HRQoL) 的显著改善.
- 在患有NP的患者中,Tezepelumab证明了鼻腔症状 (SNOT-22分数) 的降低,并且降低了FeNO和血中乙氨基酸细胞计数等生物标志物.
结论:
- 在严重的喘患者中,Tezepelumab在减少恶化和改善喘控制和HRQoL方面提供了显著的临床益处,无论鼻的息肉状况如何.
- 该药物还显示出有效性,改善了同病性NP患者的鼻腔症状.
- 捷佩卢马布是治疗严重喘的一种有前途的生物疗法,它可以治疗TSLP驱动的炎症.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
332
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
332
01:19Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343
01:20Asthma: Pathogenesis and Management
439
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
439
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K